First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli, C.
Current Opinion in Oncology 23(2): 131-132
2011
ISSN/ISBN: 1040-8746
PMID: 21307676
DOI: 10.1097/cco.0b013e328341ee26
Accession: 053252762
PDF emailed within 0-6 h: $19.90
Related References
Gao, W.; He, J.; Jin, S-Dai.; Xu, J.; Yu, T-Fu.; Wang, W.; Zhu, Q.; Dai, H.; Wu, H.; Liu, Y-Qian.; Shu, Y-Qian.; Guo, R-Hua. 2019: Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncotargets and Therapy 12: 9495-9504Gao, W.; He, J.; Jin, S.D.; Xu, J.; Yu, T.F.; Wang, W.; Zhu, Q.; Dai, H.; Wu, H.; Liu, Y.Q.; Shu, Y.Q.; Guo, R.H. 2019: Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and Egfr Exon 19 Deletion with Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors OncoTargets and Therapy Volume 12: 9495-9504
Rosell, R.; Viteri, S.; Molina, M.A.; Benlloch, S.; Taron, M. 2010: Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer Current Opinion in Oncology 22(2): 112-120
Batra, U.; Lokeshwar, N.; Gupta, S.; Shirsath, P. 2017: Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients Indian Journal of Cancer 54(Suppl): S37-S44
Lee, J-Koo.; Hahn, S.; Kim, D-Wan.; Suh, K.Jin.; Keam, B.; Kim, T.Min.; Lee, S-Hoon.; Heo, D.Seog. 2014: Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis JAMA 311(14): 1430-1437
Chen, Y.-M.; Lai, C.-H.; Chang, H.-C.; Chao, T.-Y.; Tseng, C.-C.; Fang, W.-F.; Wang, C.-C.; Chung, Y.-H.; Huang, K.-T.; Chen, H.-C.; Chang, Y.-C.; Lin, M.-C. 2015: Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Medicine 94(50): E2239
Sun, J.-M.; Park, K. 2017: Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer? Current Opinion in Oncology 29(2): 89-96
Roeper, J.; Griesinger, F. 2019: Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy? Current Opinion in Oncology 31(1): 1-7
Li, J.M.; Hu, J.; Bai, C.X.; Zhang, Y.; Xu, X.B.; Wang, X.D.; Ding, N. 2018: The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation Zhonghua Jie he He Hu Xi Za Zhi 41(10): 778-782
Xu, Z.; Hao, X.; Lin, L.; Li, J.; Xing, P. 2021: Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation Thoracic Cancer 12(16): 2233-2240
De Pas, T.; Toffalorio, F.; Manzotti, M.; Fumagalli, C.; Spitaleri, G.; Catania, C.; Delmonte, A.; Giovannini, M.; Spaggiari, L.; de Braud, F.; Barberis, M. 2011: Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 6(11): 1895-1901
Sheng, Z.; Zhang, Y. 2017: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: a Meta-analysis of 25 RCTs American Journal of Clinical Oncology 40(4): 362-369
Cohen, V.; Agulnik, J.S.; Ang, C.; Kasymjanova, G.; Batist, G.; Small, D.; Brandao, G.; Chong, G.; Miller, W.H. 2010: Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors Cancer 116(18): 4309-4317
Feng, Y.; Zhu, G.; Lang, S.; Hao, P.; Li, G.; Chen, F.; Zhuo, W.; Duan, Y.; Zhang, A.; Chen, Z.; Sun, J. 2021: The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined with Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations Frontiers in Oncology 11: 659065
Huang, A.; Li, R.; Zhao, J.; Wang, X.; Jin, B.; Niu, Y.; Zhang, J.; Jiang, L.; Han, B. 2016: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation Thoracic Cancer 7(5): 614-618
Park, S.; Lee, S.Y.; Kim, D.; Sim, Y.S.; Ryu, J.-S.; Choi, J.; Lee, S.H.; Ryu, Y.J.; Lee, J.H.; Chang, J.H. 2021: Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types Bmc Cancer 21(1): 52
Roengvoraphoj, M.; Tsongalis, G.J.; Dragnev, K.H.; Rigas, J.R. 2013: Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients Cancer Treatment Reviews 39(8): 839-850
Chang, H.-C.; Chen, Y.-M.; Tseng, C.-C.; Huang, K.-T.; Wang, C.-C.; Chen, Y.-C.; Lai, C.-H.; Fang, W.-F.; Kao, H.-C.; Lin, M.-C. 2017: Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 39(3): 1010428317695939
Alanazi, A.; Yunusa, I.; Elenizi, K.; Alzarea, A.I. 2020: Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis Lung Cancer Management 10(1): Lmt43
Pirker, R. 2016: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer Current Opinion in Oncology 28(2): 115-121